January 24, 2019

Immunomodulation Bolsters Scientific Advisory Board with Appointments of
Robert G. Petit, Ph.D. and Rex Chin-Wei Yung, M.D., F.C.C.P.

NORTHBROOK, IL, January 24, 2019 – Immunomodulation Inc. ("Immunomodulation" or the "Company"), a privately-held biopharmaceutical company focused on developing breakthrough therapies to modulate immune responses in multiple high-value oncology and serious infectious diseases, today announced the appointments of Robert G. Petit, Ph.D. and Rex Chin-Wei Yung, M.D., F.C.C.P. to its Scientific Advisory Board (SAB). 

 

July 31, 2018

Immunomodulation Therapies Announces Formation of Scientific Advisory Board and Appointment of Robert V. Stahelin, Ph.D. as Inaugural Member

NORTHBROOK, IL, July 31, 2018 – Immunomodulation Inc. ("Immunomodulation" or the "Company"), a privately-held biopharmaceutical company focused on developing breakthrough therapies to modulate immune responses in multiple high-value oncology and serious infectious diseases, today announced the formation of its Scientific Advisory Board (SAB) and appointment of Robert V. Stahelin, Ph.D., to the SAB.

 

 May 30, 2018

Immunomodulation Therapies Designed to Suppress Tumors and Fight Infection

Company Offers Corporate Overview and 2018 Business Outlook 

NORTHBROOK, IL, May 30, 2018 – Immunomodulation Inc. ("Immunomodulation" or the "Company"), a privately-held biopharmaceutical company focused on developing breakthrough therapies to modulate immune responses in multiple high-value oncology and serious infectious diseases, outlined its upcoming plans to advance its investigational product candidate, IMM-010, following consistent positive data from preclinical studies.